Advertisement

American Journal of Clinical Dermatology

, Volume 17, Issue 3, pp 265–276 | Cite as

Topical Retinoids: Therapeutic Mechanisms in the Treatment of Photodamaged Skin

  • Ryan R. RiahiEmail author
  • Amelia E. Bush
  • Philip R. Cohen
Review Article

Abstract

Retinoids are a group of substances comprising vitamin A and its natural and synthetic derivatives. Retinoids were first used in dermatology in 1943 by Straumfjord for acne vulgaris. Since that time, retinoids have been utilized in the management and treatment of various skin conditions, including photoaging. Photodamage of the skin occurs as a consequence of cumulative exposure to solar ultraviolet radiation (UVR) and is characterized by deep wrinkles, easy bruising, inelasticity, mottled pigmentation, roughness, and telangiectasias. The mechanism of UVR-induced photodamage is multifactorial. Retinoids have demonstrated efficacy in the treatment of photoaged skin. Indeed, understanding the pathophysiology of photoaging and the molecular mechanism of retinoids can not only provide insight into the effects retinoids can exert in treating photoaging but also provide the rationale for their use in the treatment of other dermatologic diseases.

Keywords

Retinoid Retinol Isotretinoin Tretinoin Alopecia Areata 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with Ethical Standards

Funding

No funding was received for the preparation of this review.

Conflict of interest

Ryan R. Riahi, Amelia E. Bush, and Philip R. Cohen have no conflicts of interest.

References

  1. 1.
    Wolverton SE (ed) Comprehensive dermatologic drug therapy. 3rd ed. Philadelphia: Saunders; 2012. p. 252–268.Google Scholar
  2. 2.
    Gericke J, Ittensohn J, Mihály J, et al. Regulation of retinoid-mediated signaling involved in skin homeostasis by RAR and RXR agonists/antagonists in mouse skin. PLoS One. 2013;8(4):e62643 (PMID 23638129).CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Sorg O, Antille C, Kaya G, Saurat JH. Retinoids in cosmeceuticals. Dermatol Ther. 2006;19(5):289–96 (PMID: 17014484).CrossRefPubMedGoogle Scholar
  4. 4.
    Griffiths CE. The role of retinoids in the prevention and repair of aged and photoaged skin. J Clin Exp Dermatol. 2001;26(7):613–8 (PMID 11696066).CrossRefGoogle Scholar
  5. 5.
    Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. J Clin Interv Aging. 2006;1(4):327–48 (PMID 18046911).CrossRefGoogle Scholar
  6. 6.
    Jain S. Topical tretinoin or adapalene in acne vulgaris: an overview. J Dermatol Treat. 2004;15(4):200–7 (PMID 15764031 ).CrossRefGoogle Scholar
  7. 7.
    Kafi R, Kwak HS, Schumacher WE, et al. Improvement of naturally aged skin with vitamin A (retinol). Arch Dermatol. 2007;143(5):606–12 (PMID 17515510).CrossRefPubMedGoogle Scholar
  8. 8.
    Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of alitretinoin gel 0.1 % in the treatment of photoaging. Cutis. 2005;76(1):69–73 (PMID 16144296).PubMedGoogle Scholar
  9. 9.
    Green C, Orchard G, Cerio R, et al. A clinicopathological study of the effects of topical retinyl propionate cream in skin photoageing. Clin Exp Dermatol. 1998;23:162–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Rajiv M, Singh N. Bexarotene gel: a new topical therapy for alopecia areata. Int J Trichol. 2010;2(1):66–7 (PMID 21188032).CrossRefGoogle Scholar
  11. 11.
    Darlenski R, Surber C, Fluhr JW. Topical retinoids in the management of photodamaged skin: from theory to evidence-based practical approach. Br J Dermatol. 2010;163(6):1157–65 (PMID 20633013).CrossRefPubMedGoogle Scholar
  12. 12.
    Sherratt MJ. Age-related tissue stiffening: cause and effect. Adv Wound Care. 2013;2(1):11–7 (PMID 24527318).CrossRefGoogle Scholar
  13. 13.
    Fisher GJ, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ. Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med. 1997;337(20):1419–28 (PMID 9358139).CrossRefPubMedGoogle Scholar
  14. 14.
    Farris PK, Rendon MI. The mechanism of action of the topical retinoids for the treatment of nonmalignant photodamage. J Cosmet Dermatol. 2010;23:108–9.Google Scholar
  15. 15.
    Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 1996;379(6563):335–9 (PMID 8552187).CrossRefPubMedGoogle Scholar
  16. 16.
    Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest. 2000;106(5):663–70 (PMID 10974019 ).CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Baldwin HE, Nighland M, Kendall C, et al. 40 years of topical tretinoin use in review. J Drugs Dermatol. 2013;12(6):638–42 (PMID: 23839179).PubMedGoogle Scholar
  18. 18.
    Inokuchi M, Ishikawa S, Furukawa H, et al. Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: a case report. Oncol Lett. 2014;7(2):444–8 (PMID 24396465).PubMedPubMedCentralGoogle Scholar
  19. 19.
    Craiglow BG, Choate KA, Milstone LM. Topical tazarotene for the treatment of ectropion ichthyosis. JAMA Dermatol. 2013;149(5):598–600. doi: 10.1001/jamadermatol.2013.239 (PMID 23677086).CrossRefPubMedGoogle Scholar
  20. 20.
    Kulka M. Mechanisms and treatment of photoaging and photodamage. In: Kulka M, editor. Using old solutions to new problems—natural drug discovery in the 21st century. Croatia: InTech; 2013. p. 255–276. doi: 10.5772/56425.
  21. 21.
    Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05 % in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol. 2005;6(4):245–53 (PMID 16060712).CrossRefPubMedGoogle Scholar
  22. 22.
    Lowe N, Gifford M, Tanghetti E, et al. Tazarotene 0.1 % cream versus tretinoin 0.05 % emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. J Cosmet Laser Ther. 2004;6(2):79–85 (PMID 15203997).CrossRefPubMedGoogle Scholar
  23. 23.
    Kang S, Krueger GG, Tanghetti EA, et al. A multicenter, randomized, double-blind trial of tazarotene 0.1 % cream in the treatment of photodamage. J Am Acad Dermatol. 2005;52(2):268–74 (PMID 15692472).CrossRefPubMedGoogle Scholar
  24. 24.
    Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01 %, 0.025 %, 0.05 %, and 0.1 % tazarotene creams with 0.05 % tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol. 2001;137(12):1597–604 (PMID 11735710).CrossRefPubMedGoogle Scholar
  25. 25.
    Kang S, Fisher GJ, Voorhees JJ. Photoaging: pathogenesis, prevention, and treatment. Clin Geriatr Med. 2001;17(4):643–59, v–vi (PMID 1153542).Google Scholar
  26. 26.
    Yaar M, Gilchrest BA. Photoageing: mechanism, prevention and therapy. Br J Dermatol. 2007;157(5):874–87.CrossRefPubMedGoogle Scholar
  27. 27.
    Poon F, Kang S, Chein A. Mechanisms and treatments of photoaging. Photodermatol Photoimmunol Photomed. 2015;31(2):65–74.CrossRefPubMedGoogle Scholar
  28. 28.
    Schmidt N, Gans EH. Tretinoin: a review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol. 2011;4(11):22–9 (PMID 22125655).PubMedPubMedCentralGoogle Scholar
  29. 29.
    Thielen AM, Saurat JH. Retinoids. In: Bolognia J, Jorizzo JL, Schaffer JV, et al., editors. Dermatology, vol. 2. 3rd ed. Philadelphia: Elsevier; 2012. p. 2089–103.Google Scholar
  30. 30.
    Herane MI, Orlandi C, Zegpi E, et al. Clinical efficacy of adapalene (differin(®)) 0.3 % gel in Chilean women with cutaneous photoaging. J Dermatol Treat. 2012;23(1):57–64. doi: 10.3109/09546634.2011.631981 (PMID 22007702).CrossRefGoogle Scholar
  31. 31.
    Bagatin E, Guadanhim LR, Enokihara MM, et al. Low-dose oral isotretinoin versus topical retinoic acid for photoaging: a randomized, comparative study. Int J Dermatol. 2014;53(1):114–22. doi: 10.1111/ijd.12191 (PMID 24168514).CrossRefPubMedGoogle Scholar
  32. 32.
    Griffiths CE, Kang S, Ellis CN, et al. Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. A double-blind, vehicle-controlled comparison of 0.1 % and 0.025 % tretinoin creams. Arch Dermatol. 1995;131(9):1037–44 (PMID 7544967).CrossRefPubMedGoogle Scholar
  33. 33.
    Nyirady J, Bergfeld W, Ellis C, et al. Tretinoin cream 0.02 % for the treatment of photodamaged facial skin: a review of 2 double-blind clinical studies. Cutis. 2001;68(2):135–42 (PMID 11534915).PubMedGoogle Scholar
  34. 34.
    Sorg O, Saurat J-H. Topical retinoids in skin ageing: a focused update with reference to sun-induced epidermal vitamin A deficiency. Dermatology. 2014;228(4):314–25.CrossRefPubMedGoogle Scholar
  35. 35.
    Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochimica et Biophysica Acta. 2004;1703(1):1–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Ross AC. Retinoid production and catabolism: role of diet in regulating retinol esterification and retinoic Acid oxidation. J Nutr. 2003;133(1):291S–6S.PubMedGoogle Scholar
  37. 37.
    Iskakova M, Karbyshev M, Piskunov A, Rochette-Egly C. Nuclear and extranuclear effects of vitamin A. Can J Physiol Pharmacol. 2015;93(12):1065–75 (PMID: 26459513).CrossRefPubMedGoogle Scholar
  38. 38.
    Tsuji M, Shudo K, Kagechika H. Docking simulations suggest that all-trans retinoic acid could bind to retinoid X receptors. J Computer-Aided Mol Design. 2015;29(10):975–88. doi: 10.1007/s10822-015-9869-9 (PMID: 26384496).CrossRefGoogle Scholar
  39. 39.
    Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature. 1990;345:224–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Amano Y, Noguchi M, Nakagomi M, Muratake H, Fukasawa H, Shudo K. Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures. Bioorganic Med Chem. 2013;21:4342–50.CrossRefGoogle Scholar
  41. 41.
    Allegretto EA, McClurg MR, Lazarchik SB, et al. Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J Biol Chem. 1993;268:26625–33.PubMedGoogle Scholar
  42. 42.
    Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992;68:397–40624.CrossRefPubMedGoogle Scholar
  43. 43.
    Kawamura K, Shiohara M, Kanda M, Fujiwara S. Retinoid X receptor-mediated transdifferentiation cascade in budding tunicates. Develop Biol. 2013;384:343–55.CrossRefPubMedGoogle Scholar
  44. 44.
    Mizuguchi Y, Wada A, Nakagawa K, Ito M, Okano T. Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60. Biol Pharm Bull. 2006;29:1803–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Kaya G, Saurat JH. Dermatoporosis: a chronic cutaneous insufficiency/fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments. Dermatology. 2007;215:284–94.CrossRefPubMedGoogle Scholar
  46. 46.
    Quan T, Qin Z, Shao Y, Xu Y, Voorhees JJ, Fisher GJ. Retinoids suppress cysteine-rich protein 61 (CCN1), a negative regulator of collagen homeostasis, in skin equivalent cultures and aged human skin in vivo. Exp Dermatol. 2011;20(7):572–6.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Shim JH, Shin DW, Noh MS, Lee TR. Reduced collagen internalization via down-regulation of MRC2 expression by UVA irradiation and its recovery by all-trans retinoic acid. J Dermatol Sci. 2014;73(2):163–6 (PMID: 24161566).CrossRefPubMedGoogle Scholar
  48. 48.
    Qin Z, Fisher GJ, Quan T. Cysteine-rich protein 61 (CCN1) domain-specific stimulation of matrix metalloproteinase-1 expression through αVβ3 integrin in human skin fibroblasts. J Biol Chem. 2013;288(17):12386–94.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Qin Z, Okubo T, Voorhees JJ, Fisher GJ, Quan T. Elevated cysteine-rich protein 61 (CCN1) promotes skin aging via upregulation of IL-1β in chronically sun-exposed human skin. Age. 2013;36(1):353–64.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Chung JH, Eun HC. Angiogenesis in skin aging and photoaging. J Dermatol. 2007;34(9):593–600.CrossRefPubMedGoogle Scholar
  51. 51.
    Wang Z, Boudjelal M, Kang S, Voorhees JJ, Fisher GJ. Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment. Nat Med. 1999;5(4):418–22.CrossRefPubMedGoogle Scholar
  52. 52.
    Gilchrest B. Anti-sunshine vitamin A. Nat Med. 1999;5(4):376–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Wójcik A, Bartnicka E, Namieciński P, Rotsztejn H. Influence of the complex of retinol-vitamin C on skin surface lipids. J Cosmet Dermatol. 2015;14(2):92–9 (PMID: 25810364).CrossRefPubMedGoogle Scholar
  54. 54.
    Bubna AK. Alitretinoin in dermatology—an update. Indian J Dermatol. 2015;60(5):520 (PMID: 26538721).CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Bouloc A, Vergnanini AL, Issa MC. A double-blind randomized study comparing the association of Retinol and LR2412 with tretinoin 0.025 % in photoaged skin. J Cosmet Dermatol. 2015;14(1):40–6. doi: 10.1111/jocd.12131 (PMID: 25603890).CrossRefPubMedGoogle Scholar
  56. 56.
    Randhawa M, Rossetti D, Leyden JJ, et al. One-year topical stabilized retinol treatment improves photodamaged skin in a double-blind, vehicle-controlled trial. J Drugs Dermatol. 2015;14(3):271–80 (PubMed PMID: 25738849).PubMedGoogle Scholar
  57. 57.
    Babcock M, Mehta RC, Makino ET. A randomized, double-blind, split-face study comparing the efficacy and tolerability of three retinol-based products vs. three tretinoin-based products in subjects with moderate to severe facial photodamage. J Drugs Dermatol. 2015;14(1):24–30 (PMID: 25607905).PubMedGoogle Scholar
  58. 58.
    Ho ET, Trookman NS, Sperber BR, et al. A randomized, double-blind, controlled comparative trial of the anti-aging properties of non-prescription tri-retinol 1.1 % vs. prescription tretinoin 0.025 %. J Drugs Dermatol. 2012;11(1):64–9 (PMID: 22206079).PubMedGoogle Scholar
  59. 59.
    Katz BE, Lewis J, McHugh L, Pellegrino A, Popescu L. The tolerability and efficacy of a three-product anti-aging treatment regimen in subjects with moderate-to-severe photodamage. J Clin Aesthet Dermatol. 2015;8(10):21–6 (PMID: 26557215).PubMedPubMedCentralGoogle Scholar
  60. 60.
    Bravo BS, Azulay DR, Luiz RR, Mandarim-De-Lacerda CA, Cuzzi T, Azulay MM. Oral isotretinoin in photoaging: objective histological evidence of efficacy and durability. Anais Brasileiros de Dermatologia. 2015;90(4):479–86. doi: 10.1590/abd1806-4841.20153703 (PMID: 26375216).CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Kim MS, Lee S, Rho HS, Kim DH, Chang IS, Chung JH. The effects of a novel synthetic retinoid, seletinoid G, on the expression of extracellular matrix proteins in aged human skin in vivo. Clin Chim Acta. 2005;362(1-2):161–9 (PMID 16055107).CrossRefPubMedGoogle Scholar
  62. 62.
    Chandraratna RA. Current research and future developments in retinoids: oral and topical agents. Cutis. 1998;61(2 Suppl):40–5 (Review. PMID: 9787993).PubMedGoogle Scholar
  63. 63.
    Tsai FM, Wu CC, Shyu RY, et al. Tazarotene-induced gene 1 inhibits prostaglandin E2-stimulated HCT116 colon cancer cell growth. J Biomed Sci. 2011;18:88. doi: 10.1186/1423-0127-18-88 (PMID 2212630).CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Nagpal S, Patel S, Jacobe H, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Investig Dermatol. 1997;109(1):91–5.CrossRefPubMedGoogle Scholar
  65. 65.
    Scharadin TM, Eckert RL. TIG3: an important regulator of keratinocyte proliferation and survival. J Investig Dermatol. 2014. doi: 10.1038/jid.2014.79 (PMID 24599174).
  66. 66.
    Duvic M, Ni X, Talpur R, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Investig Dermatol. 2003;121(4):902–9 (PMID 14632211).CrossRefPubMedGoogle Scholar
  67. 67.
    Hung CF, Chen WY, Hsu CY, Aljuffali IA, Shih HC, Fang JY. Cutaneous penetration of soft nanoparticles via photodamaged skin: lipid-based and polymer-based nanocarriers for drug delivery. Eur J Pharm Biopharm. 2015;94:94–105 (PMID: 25986584).CrossRefPubMedGoogle Scholar
  68. 68.
    Raza K, Singh B, Lohan S, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456(1):65–72 (PMID: 23973754).CrossRefPubMedGoogle Scholar
  69. 69.
    Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly A. Tretinoin-loaded liposomal formulations: from lab to comparative clinical study in acne patients. Drug Deliv. 2015;25:1–10 (PMID: 26004128).CrossRefGoogle Scholar
  70. 70.
    Sorg O, Kuenzli S, Saurat JH. Side effects and pitfalls in retinoid therapy. In: Vahlquist A, Duvic M, editors. Retinoids and carotenoids in dermatology, chapter 13. New York: Informa Healthcare; 2007. p. 225–48.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Ryan R. Riahi
    • 1
    Email author
  • Amelia E. Bush
    • 2
  • Philip R. Cohen
    • 3
  1. 1.Department of DermatologyLouisiana State UniversityNew OrleansUSA
  2. 2.University of Texas Medical School at HoustonHoustonUSA
  3. 3.Department of DermatologyUniversity of California San DiegoSan DiegoUSA

Personalised recommendations